Secondary TMA Screening
A number of conditions are known to cause a secondary TMA. We recommend that screening for secondary causes of TMA is sent promptly at time of referral as listed on our diagnostic checklist. As part of our referral pathway for new patients with suspected aHUS, eculizumab may be commenced promptly before all of the results of screening for secondary causes of TMA are available.
We aim to review these results in the first month following referral. There is currently no evidence that patients with a secondary TMA benefit from treatment with eculizumab. In patients that have already been commenced on eculizumab where a secondary cause of TMA has been identified it may be possible to stop treatment.
Causes of TMA